Intelligence Feed event · Policy · 2026-09-09

    FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy

    Question

    FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy

    Direct answer

    The FDA granted label expansion for Casgevy, the CRISPR-based therapy co-developed by CRISPR Therapeutics and Vertex Pharmaceuticals, extending eligible administration down to pediatric patients aged 2 and older. The decision broadens clinical adoption pathways across qualified treatment centers. Commercial momentum accelerated in the second quarter, with Casgevy revenue climbing 78% quarter-over-quarter to $76 million. The expanded label provides therapeutic access to earlier-stage cohorts, reinforcing medium-term cash flow generation.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/fda-approves-label-expansion-for-crispr-therapeutics-gene-therapy-casgevy-8f0fc1

    POLICY
    FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy
    The FDA granted label expansion for Casgevy, the CRISPR-based therapy co-developed by CRISPR Therapeutics and Vertex Pharmaceuticals, extending eligible administration down to pediatric patients aged 2 and older. The decision broadens clinical adoption pathways across qualified treatment centers. Commercial momentum accelerated in the second quarter, with Casgevy revenue climbing 78% quarter-over-quarter to $76 million. The expanded label provides therapeutic access to earlier-stage cohorts, reinforcing medium-term cash flow generation.
    CRSPVRTX
    Impact
    69
    SEP 9
    SIG
    88%
    CRSPVRTX
    FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy
    The FDA granted label expansion for Casgevy, the CRISPR-based therapy co-developed by CRISPR Therapeutics and Vertex Pharmaceuticals, extending eligible administration down to pediatric patients aged 2 and older. The decision broadens clinical adoption pathways across qualified treatment centers. Commercial momentum accelerated in the second quarter, with Casgevy revenue climbing 78% quarter-over-quarter to $76 million. The expanded label provides therapeutic access to earlier-stage cohorts, reinforcing medium-term cash flow generation.
    → Broadening FDA label eligibility to pediatric patients expands the commercial addressable market, accelerating royalty and product revenue inflows for CRSP and partner VRTX.
    Impact
    The FDA granted label expansion for Casgevy, the CRISPR-based therapy co-developed by CRISPR Therapeutics and Vertex Pharmaceuticals, extending eligible administration down to pediatric patients aged 2 and older. The decision broadens clinical adoption pathways across qualified treatment centers. Commercial momentum accelerated in the second quarter, with Casgevy revenue climbing 78% quarter-over-quarter to $76 million. The expanded label provides therapeutic access to earlier-stage cohorts, reinforcing medium-term cash flow generation.
    Affected
    CRSPVRTX
    Transmission
    Broadening FDA label eligibility to pediatric patients expands the commercial addressable market, accelerating royalty and product revenue inflows for CRSP and partner VRTX.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial market expansion via FDA label approvalUp1-3mFDA approved pediatric label expansion for Casgevy following 78% QoQ revenue growth to $76M.
    VRTXco-commercialization revenue share expansionUp1-3mVertex co-develops and commercializes Casgevy alongside CRISPR Therapeutics.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month